Evotec SE, a prominent German pharmaceutical company, has announced notable advancements in its strategic alliance with Bristol Myers Squibb, aimed at creating a pipeline centered around molecular glue technology. Due to its performance and achievement of program-based milestones, Evotec is set to receive $75 million in payments.
The partnership, established in 2018, combines Evotec's cutting-edge multi-omics screening and analytical capabilities with Bristol Myers Squibb's top-tier collection of cereblon E3 ligase modulators.
In 2022, the collaboration was expanded to continue focusing on the discovery of pioneering molecular glue degraders, targeting high-value areas in oncology and other sectors. The recent milestones achieved underline the strength and progress of Evotec's shared pipeline initiatives.
